Diabetic ketoacidosis associated with empagliflozin therapy : mechanisms, risc factors and clinical implications
Abstract
Empagliflozin, a sodium–glucose co-transporter 2 (SGLT2) inhibitor, is widely prescribed for type 2 diabetes mellitus (T2DM) and heart failure. Despite its proven cardiovascular and renal benefits, rare but serious cases of diabetic ketoacidosis (DKA), including euglycemic DKA (euDKA), have been reported. This article reviews the incidence, mechanisms, risk factors, clinical features, and management strategies of empagliflozin-associated DKA. Early recognition and preventive strategies are essential to balance risks and benefits of therapy.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.